179 related articles for article (PubMed ID: 8787895)
1. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
3. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination.
Bourget P; Sertin A; Lesne-Hulin A; Fernandez H; Ville Y; Van Peborgh P
Eur J Obstet Gynecol Reprod Biol; 1998 Jan; 76(1):21-7. PubMed ID: 9481541
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
J Antimicrob Chemother; 2001 Aug; 48(2):259-67. PubMed ID: 11481298
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characteristics of piperacillin/tazobactam.
Sörgel F; Kinzig M
Intensive Care Med; 1994 Jul; 20 Suppl 3():S14-20. PubMed ID: 7962984
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
10. Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement.
Dalley AJ; Lipman J; Venkatesh B; Rudd M; Roberts MS; Cross SE
J Antimicrob Chemother; 2007 Jul; 60(1):166-9. PubMed ID: 17504805
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of piperacillin in burn patients.
Jeon S; Han S; Lee J; Hong T; Paek J; Woo H; Yim DS
Antimicrob Agents Chemother; 2014 Jul; 58(7):3744-51. PubMed ID: 24752260
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics].
Iwai N; Nakamura H; Miyazu M
Jpn J Antibiot; 1998 May; 51(5):346-61. PubMed ID: 9693967
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
17. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].
Pédeboscq S; Dubau B; Frappier S; Hernandez V; Veyssières D; Winnock S; Pometan JP
Pathol Biol (Paris); 2001 Sep; 49(7):540-7. PubMed ID: 11642016
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
20. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease.
Johnson CA; Halstenson CE; Kelloway JS; Shapiro BE; Zimmerman SW; Tonelli A; Faulkner R; Dutta A; Haynes J; Greene DS
Clin Pharmacol Ther; 1992 Jan; 51(1):32-41. PubMed ID: 1310077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
